The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 8, 2004, Pages 1407-1411

  Hirose, Kaoru ^a   Matsuo, Keitaro ^a   Toyama, Tatsuya ^a   Iwata, Hiroji ^a   Hamajima, Nobuyuki ^b   Tajima, Kazuo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ARGININE; AROMATASE; CYTOCHROME P450; ESTROGEN; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CODON; CONTROLLED STUDY; CYP19 GENE; ESTROGEN SYNTHESIS; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; JAPAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; RARE DISEASE; STATISTICAL ANALYSIS;

ADULT; AGE FACTORS; AGED; AROMATASE; BASE SEQUENCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CODON; CONFIDENCE INTERVALS; DNA, NEOPLASM; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JAPAN; LOGISTIC MODELS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; REFERENCE VALUES; RISK ASSESSMENT;

EID: 4043092284     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kirshner MA, Ertel N, Schneider G. Obesity, hormones and cancer. Cancer Res 1981;41:3711-7.
2. Zumoff B. Relationship of obesity to blood estrogen. Cancer Res 1982;42 Suppl:3289s-94s.
3. Bruning PF. Endogenous estrogens and breast cancer, a possible relationship between body-fat distribution and estrogen availability. J Steroid Biochem 1987;27:487-92.
4. Polymeropoulos MH, Xiao H, Ragh DS, Merril CR. Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19). Nucleic Acids Res 1991;19:195.
5. Corbin CJ, Graham-Lorence S, McPhaul M, Manson JI, Mendelson CR, Simpson ER. Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. Proc Natl Acad Sci USA 1988;85:8948-52.
6. Means GD, Mahendroo MS, Corbin CJ, et al. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol Chem 1989;264:19385-91.
7. Sourdaine P, Parker MG, Telford J, Miller WR. Analysis of the aromatase cytochrome P450 gene in human breast cancer. J Mol Endocrinol 1994;13:331-7.
8. Watanabe J, Harada N, Suemasu K, Higashi Y, Gotoh O, Kawajiri K. Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. Pharmacogenetics 1997;7:419-24.
9. Kristensen VN, Andersen TI, Lindbleom A, Erikstein B, Magnus P, Borresen-Dale A-L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998;8:43-8.
10. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (CYP19) and breast cancer. Br J Cancer 1999;79:456-63.
11. Baxter SW, Choong DYH, Eccles DM, Campbel LG. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001;22:347-9.
12. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 2000;89:325-8.
13. Moolgavkar SJ, Stevems RG, Lee JAH. Effect of age on incidence of breast cancer in females. J Natl Cancer Inst 1979;62:493-501.
14. Tajima K, Hirose K, Inoue M, Takezaki T, Hamajima N, Kuroishi T. A model of practical cancer prevention for out-patients visiting a hospital: the Hospital-Based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Asian Pac J Cancer Prev 2000;1:35-47.
15. Hamajima N, Matsuo K, Saito T, et al. Gene-environment interactions and polymorphism studies of cancer risk in the Hospital-Based Epidemiologic Research Program at Aichi Cancer Center II (HERPACC-II). Asian Pac J Cancer Prev 2001;2:99-107.
16. Hirose K, Tajima K, Hamajima N, et al. Effect of body size on breast-cancer risk among Japanese women. Int J Cancer 1999;80:349-55.
17. Hamajima N, Iwata H, Obata Y, et al. No association of the 5′ promoter region polymorphism of CYF17 with breast cancer risk in Japan. Jpn J Cancer Res 2000;91:880-5.
18. Hamajima N, Saito T, Matsuo K, Kozaki K, Takahashi T, Tajima K. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res 2000;91:865-8.
19. Inoue M, Tajima K, Hirose K, et al. Epidemiological features of first-visit outpatients in Japan: comparison with general population and variation by sex, age, and season. J Clin Epidemiol 1997;50:69-77.
20. Yoo KY, Tajima K, Miura S, et al. Breast cancer risk factors according to estrogen and progesterone receptor status: a case-control analysis. Am J Epidemiol 1997;146:307-14.
21. Haiman CA, Hankinson SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000;87:204-10.
22. Healey CS, Dunning AM, Durocher F, et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 2000;21:189-93.